Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
针对 SARS-CoV-2 的治疗性抗体的临床前安全性和有效性,该抗体在 Sotrovimab 表面被 Omicron 所逃避
期刊:iScience
影响因子:4.6
doi:10.1016/j.isci.2023.106323
Jakob Kreye, S Momsen Reincke, Stefan Edelburg, Lara M Jeworowski, Hans-Christian Kornau, Jakob Trimpert, Peter Hombach, Sophia Halbe, Volker Nölle, Martin Meyer, Stefanie Kattenbach, Elisa Sánchez-Sendin, Marie L Schmidt, Tatjana Schwarz, Ruben Rose, Andi Krumbholz, Sophie Merz, Julia M Adler, Kath